We are thrilled to announce that we have successfully prepared a day one launch of the generic version of Teriflunomide in more than 20 European countries!
This complex launch follows Tiefenbacher Group`s strategy to make high quality pharmaceuticals better affordable and better available for patients worldwide.
Teriflunomide is used to treat Multiple Sclerosis – a chronic disease that effects the central nervous system. The 14 mg film coated tablets are developed and produced in Tiefenbacher Group`s own sites and will be marketed by our partners, well-known international pharmaceutical companies. Our product has already been successfully launched in the US, Canada, Mexico, and Australia before. Further markets will follow shortly.
AET TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes affordable high-quality healthcare solutions as well as medical devices worldwide. We provide over 180+ pharmaceuticals products across various therapeutic categories in 40+ dosage forms. With our in-house product development, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines including high-potent for global markets.
For more information around our finished dosage forms and healthcare solutions, please contact AET Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or please visit us on: www.tiefenbacher-pharmaceuticals.com
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.
